Sequential therapy for hepatocellular carcinoma -Real world evidence of TKI in prospective observational study-

Sequential therapy for hepatocellular carcinoma -Real world evidence of TKI in prospective observational study- - HAMRET study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038867

Enrollment

500

Registered

2020-01-01

Start date

2020-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: #1.Diagnosed with HCC histologically or clinically (image diagnosis and tumor marker) #2.Scheduled for systemic therapy for HCC #3.Patients who obtained written informed consent for this clinical study

Exclusion criteria

Exclusion criteria: #1.Patients with a past history of treatment for systemic therapy #2.Patients participating in another interventional clinical trials

Design outcomes

Primary

Measure	Time frame
Overall survival from 1st line treatment (including subsequent therapies)	—

Countries

Japan

Contacts

Public ContactShinji Itoh

Graduate School of Medical Sciences, Kyushu University Department of Surgery and Science, Graduate School of Medical Sciences

itoshin@surg2.med.kyushu-u.ac.jp092-642-5466

Outcome results